MedPath

Boehringer Ingelheim USA Corporation

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 638683 or placebo
Drug: Placebo solution
First Posted Date
2010-09-06
Last Posted Date
2011-06-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
63
Registration Number
NCT01195688
Locations
๐Ÿ‡ฉ๐Ÿ‡ช

1279.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 10773 (low)
Drug: BI 10773 Placebo
Drug: Moxifloxacin
Drug: BI 10773 (high)
First Posted Date
2010-09-06
Last Posted Date
2014-07-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT01195675
Locations
๐Ÿ‡ฉ๐Ÿ‡ช

1245.16.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Linagliptin
Drug: Placebo
First Posted Date
2010-09-03
Last Posted Date
2014-01-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
234
Registration Number
NCT01194830
Locations
๐Ÿ‡บ๐Ÿ‡ธ

1218.75.053 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

1218.75.102 Boehringer Ingelheim Investigational Site, Tomball, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

1218.75.037 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States

and more 90 locations

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Phase 2
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: BI 10773
Drug: Placebo (mid dose)
Drug: Placebo (high dose)
Drug: Placebo (low dose)
First Posted Date
2010-09-01
Last Posted Date
2014-06-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
547
Registration Number
NCT01193218
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

1245.38.003 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

1245.38.032 Boehringer Ingelheim Investigational Site, Okawa, Fukuoka, Japan

๐Ÿ‡ฏ๐Ÿ‡ต

1245.38.012 Boehringer Ingelheim Investigational Site, Sasima-gun, Ibaraki, Japan

and more 29 locations

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Phase 3
Completed
Conditions
Parkinson Disease
Interventions
Drug: pramipexole extended release tablet
Drug: pramipexole immediate release tablet
First Posted Date
2010-08-31
Last Posted Date
2014-10-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
475
Registration Number
NCT01191944
Locations
๐Ÿ‡จ๐Ÿ‡ณ

248.671.86013 Boehringer Ingelheim Investigational Site, Chongqing, China

๐Ÿ‡จ๐Ÿ‡ณ

248.671.86012 Boehringer Ingelheim Investigational Site, Chengdu, China

๐Ÿ‡จ๐Ÿ‡ณ

248.671.86014 Boehringer Ingelheim Investigational Site, Chongqing, China

and more 17 locations

Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 113823
Drug: BI 113823 + Ketokonazole
First Posted Date
2010-08-26
Last Posted Date
2013-11-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT01189175
Locations
๐Ÿ‡ฉ๐Ÿ‡ช

1272.5.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 10773/linagliptin
Drug: BI 10773/linagliptin FDC
Drug: BI 10773/linagliptin SID
First Posted Date
2010-08-26
Last Posted Date
2015-03-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
42
Registration Number
NCT01189201
Locations
๐Ÿ‡ฉ๐Ÿ‡ช

1275.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Phase 4
Completed
Conditions
Arthroplasty, Replacement
Prevention of Venous Thromboembolism
Moderate Renal Impairment (CrCl 30-50 mL/Min)
Interventions
Drug: Dabigatran etexilate
First Posted Date
2010-08-19
Last Posted Date
2018-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
142
Registration Number
NCT01184989
Locations
๐Ÿ‡ซ๐Ÿ‡ฎ

1160.86.35801 Boehringer Ingelheim Investigational Site, Jyvรคskylรค, Finland

๐Ÿ‡จ๐Ÿ‡ฆ

1160.86.01001 Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada

๐Ÿ‡จ๐Ÿ‡ฆ

1160.86.01002 Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada

and more 7 locations

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

First Posted Date
2010-08-17
Last Posted Date
2014-10-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
936
Registration Number
NCT01183013
Locations
๐Ÿ‡บ๐Ÿ‡ธ

1264.3.01006 Boehringer Ingelheim Investigational Site, Norwalk, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

1264.3.01044 Boehringer Ingelheim Investigational Site, Charlotte, North Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

1264.3.01084 Boehringer Ingelheim Investigational Site, Cartersville, Georgia, United States

and more 129 locations

Telmisartan, Amlodipine and Combination in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: amlodipine/telmisartan/combination
First Posted Date
2010-08-13
Last Posted Date
2014-07-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
28
Registration Number
NCT01181011
Locations
๐Ÿ‡จ๐Ÿ‡ณ

1235.30.86001 Boehringer Ingelheim Investigational Site, Shanghai, China

ยฉ Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy